Glycerolipid Lipases

MAGL Inhibitor Compound 23 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL Inhibitor Compound 23 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL Inhibitor Compound 23 blocks MAGL in cell-based as well as in vivo assays.

(R)-KT109 is the (R) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109.

(S)-KT109 is the (S) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109.

Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors.

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position.

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position.

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position.

KIAA1363 is a 2-acetyl monoacylglyceryl ether (MAGE) hydrolase that is upregulated in aggressive cancers from various tissues.

An ABHD12 inhibitor

An inhibitor of MAGL

A bacterial metabolite with diverse biological activities

An internal standard for the quantification of orlistat

JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor.